Commercial Insight: Top 20 Oncology Therapy Brands in Australia

The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008, growing at a CAGR of 30% since 2005. Datamonitor forecasts this growth to slow down considerably to a CAGR of 5.6% between 2008 and 2018 mainly due to maturing markets and the entry of generics for several key products. Sales of the Top 20 brands are expected to reach a total of $940m in 2018.

Scope

*This report focuses on the Top 20 cancer therapy brands in Australia sales and volume forecasts to 2018

*Assessment of Australia-specific drivers and resistors likely to impact the market

*Future market outlook for individual products taking into account key market events, in particular indication expansion and patent expiry

*Case study examining the approval and reimbursement process in Australia

Highlights

Datamonitor forecasts that the molecular targeted therapies will continue to drive growth in the Australian Top 20 cancer therapies market over the forecast period 20082018, with sales increasing from $320m in 2008 to $750m 2018.

The highest-selling brand in Australia in 2008 was Herceptin (trastuzumab; Roche) with sales of just under $120m and a CAGR between 2005 and 2008 of 61%. This drug is well positioned in the HER-2-positive breast cancer market where it received an exceptional reimbursement status.

In 2018, the Australian Top 20 will be led by Rituxan/MabThera (rituximab; Roche) with sales of $225m, followed by Avastin (bevacizumab; Roche) and Herceptin with revenues of $190m and $160m, respectively. Avastin will be the fastest growing brand with a 20082018 CAGR of 38% due to aggressive indication expansion in the coming years.

Reasons to Purchase

*Identify key opportunities and threats that will impact the Australian oncology market as a whole and the Top 20 in particular

*Quantify the future size and scope of the Top 20 Australian cancer therapies market and predict the performance of its key compounds

*Understand critical success factors in growing and defending cancer brand franchises from new entrants and generics